[S-27] Current topics in Guillain-Barré syndrome - from pathophysiology to clinical features

[S-27-5] Guillain-Barré syndrome in Japan; clinical features and prediction of prognosis

Yuko Yamagishi¹, Motoi Kuwahara¹, Hidekazu Suzuki^1,2, Makoto Samukawa¹, Japanese GBS study group Japanese GBS study group³, Susumu Kusunoki¹ (1.Department of Neurology, Kindai University, Faculty of Medicine, Japan, 2.Department of Neurology, Ikuwakai Memorial Hospital, 3.Japanese GBS study group)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

Dr. Yamagishi is currently an assistant professor in the department of Neurology, Kindai University, Faculty of Medicine, Osaka, Japan.
Dr. Yamagishi graduated from Kindai university Faculty of Medicine in 2009 and obtained her PhD degree in 2017. She had worked in Toyonaka municipal hospital from 2011 to 2014 as a resident staff. She has engaged in clinical neurology and basic research in Kindai university from 2017 to 2018. She then engaged in research of Guillain-Barre syndrome as a research associate in Prof. Jacobs’s lab, Department of Immunology, Erasmus MC, Rotterdam, Netherlands. After returning to Kindai University, she engaged in clinical neurology. Her research interest focuses on the clinical characteristics of Guillain-Barre syndrome and Parkinson’s disease.